| Year |
Citation |
Score |
| 2024 |
Gomez SM, Drewry DH, Willson TM, Major MB, Townsend RR, Sorger PK, Johnson GL. Illuminating function of the understudied druggable kinome. Drug Discovery Today. 103881. PMID 38218213 DOI: 10.1016/j.drudis.2024.103881 |
0.367 |
|
| 2023 |
Joisa CU, Chen KA, Beville S, Stuhlmiller T, Berginski ME, Okumu D, Golitz BT, Johnson GL, Gomez SM. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. Biorxiv : the Preprint Server For Biology. PMID 37577663 DOI: 10.1101/2023.08.01.551346 |
0.306 |
|
| 2022 |
Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-anilino-quin(az)oline as a cell active Protein Kinase Novel 3 (PKN3) inhibitor chemotype. Chemmedchem. PMID 35403825 DOI: 10.1002/cmdc.202200161 |
0.306 |
|
| 2021 |
East MP, Johnson GL. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. The Journal of Biological Chemistry. 101525. PMID 34958800 DOI: 10.1016/j.jbc.2021.101525 |
0.404 |
|
| 2020 |
Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics. PMID 32847978 DOI: 10.1158/1535-7163.Mct-19-1017 |
0.357 |
|
| 2020 |
Goulet DR, Foster JP, Zawistowski JS, Bevill SM, Noel MP, Olivares-Quintero JF, Sciaky N, Singh D, Santos C, Pattenden SG, Davis IJ, Johnson GL. Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research : McR. PMID 32753473 DOI: 10.1158/1541-7786.Mcr-19-1011 |
0.372 |
|
| 2020 |
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, ... ... Johnson GL, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. The Journal of Clinical Investigation. PMID 32573490 DOI: 10.1172/Jci130323 |
0.315 |
|
| 2020 |
Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Herrera Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, Yeh JJ. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Jci Insight. PMID 32213714 DOI: 10.1172/Jci.Insight.129905 |
0.427 |
|
| 2020 |
Yesilkanal AE, Yang D, Tiwari P, Sabino AU, Lee J, Xie X, Sun S, Dann C, Steinberg E, Stuhlmiller T, Frankenberger C, Goldsmith E, Johnson GL, Ramos AF, Rosner M. Abstract 5038: Limited inhibition of multiple nodes in a driver network blocks metastasis Cancer Research. 80: 5038-5038. DOI: 10.1158/1538-7445.Am2020-5038 |
0.407 |
|
| 2019 |
Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Targeted Oncology. PMID 31429028 DOI: 10.1007/S11523-019-00662-4 |
0.331 |
|
| 2019 |
Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31346082 DOI: 10.1073/Pnas.1903991116 |
0.358 |
|
| 2019 |
Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Molecular Cancer Research : McR. PMID 31000582 DOI: 10.1158/1541-7786.Mcr-18-1121 |
0.39 |
|
| 2019 |
Asquith CRM, Naegeli K, East M, Laitinen T, Havener T, Wells C, Johnson G, Drewry D, Zuercher W, Morris D. Design of a cyclin G associated kinase (GAK)/epidermal growth factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. Journal of Medicinal Chemistry. PMID 30973735 DOI: 10.1021/Acs.Jmedchem.9B00350 |
0.393 |
|
| 2019 |
Smithberger E, Shelton AK, Butler MK, Flores AR, Bash RE, Angus SP, Sciaky N, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 3019: Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy Cancer Research. 79: 3019-3019. DOI: 10.1158/1538-7445.Sabcs18-3019 |
0.461 |
|
| 2019 |
Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson GL, Berens ME, Furnari F, Miller CR. Abstract 331: Dynamic kinome targeting reveals kinases involved in acquired resistance to tyrosine kinase inhibitors in EGFR-driven glioblastomas Cancer Research. 79: 331-331. DOI: 10.1158/1538-7445.Am2019-331 |
0.39 |
|
| 2019 |
Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, East M, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Ryan Miller C. DRES-13. DUAL KINASE INHIBITION TO COMBAT EGFR-INHIBITOR RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 21: vi74-vi74. DOI: 10.1093/Neuonc/Noz175.300 |
0.483 |
|
| 2018 |
Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, ... ... Johnson GL, et al. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas. Human Molecular Genetics. PMID 30335132 DOI: 10.1093/Hmg/Ddy361 |
0.386 |
|
| 2018 |
Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, et al. Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. Slas Discovery : Advancing Life Sciences R & D. 2472555218773045. PMID 29742358 DOI: 10.1177/2472555218773045 |
0.325 |
|
| 2018 |
Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM. Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. Oncotarget. 9: 15480-15497. PMID 29643987 DOI: 10.18632/Oncotarget.24337 |
0.435 |
|
| 2018 |
Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, ... ... Johnson GL, et al. Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers. Cancer Research. PMID 29472518 DOI: 10.1158/0008-5472.Can-17-1990 |
0.41 |
|
| 2018 |
Ahmad S, St Hilaire VR, Dandepally SR, Johnson GL, Williams AL, Scott JE. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). Biochemical and Biophysical Research Communications. PMID 29309787 DOI: 10.1016/J.Bbrc.2018.01.027 |
0.415 |
|
| 2018 |
Zawistowski J, Bevill S, Johnson GL. Abstract IA23: Enhancer remodeling in response to MEK inhibition in TNBC Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia23 |
0.428 |
|
| 2018 |
Bevill SM, Sciaky N, Golitz BT, Rashid NU, Zawistowski JS, Johnson GL. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B34 |
0.404 |
|
| 2018 |
Smithberger E, Flores AR, Butler MK, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 2372: Kinome profiling of non-germline, genetically engineered mouse models of glioblastoma driven by Cdkn2a, Egfr, and/or Pten mutations reveals genotype-dependent kinase targets Cancer Research. 78: 2372-2372. DOI: 10.1158/1538-7445.Am2018-2372 |
0.44 |
|
| 2018 |
Matkar S, Sano R, Larmour C, Krytska K, Witek GM, Gerelus M, Stuhlmiller TJ, Johnson GL, Mosse YP. Abstract 1633: Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas Cancer Research. 78: 1633-1633. DOI: 10.1158/1538-7445.Am2018-1633 |
0.481 |
|
| 2018 |
Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-08. DYNAMIC KINOME PROFILING OF GENETICALLY-DEFINED, EGFRvIII-DRIVEN MURINE ASTROCYTE MODELS OF GLIOBLASTOMA REVEALS TARGETS FOR DUAL KINASE INHIBITOR THERAPY Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.315 |
0.354 |
|
| 2018 |
Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-07. DEFINING THE MECHANISMS OF ACQUIRED RESISTANCE TO TYROSINE KINASE INHIBITORS IN EGFR-DRIVEN GLIOBLASTOMAS USING INTEGRATED KINOME AND TRANSCRIPTOME PROFILING Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.314 |
0.392 |
|
| 2017 |
Bevill SM, Zawistowski JS, Johnson GL. Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622. PMID 29209639 DOI: 10.1080/23723556.2017.1300622 |
0.475 |
|
| 2017 |
Bevill SM, Zawistowski JS, Johnson GL. Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622. PMID 29209639 DOI: 10.1080/23723556.2017.1300622 |
0.372 |
|
| 2017 |
Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr D, Karagoz K, Sciaky N, Gatza M, Sharpless NE, Johnson GL, Bear JE. New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Research. PMID 29180473 DOI: 10.1158/0008-5472.Can-17-1653 |
0.343 |
|
| 2017 |
Cousins EM, Goldfarb D, Yan F, Roques J, Darr DB, Johnson GL, Major MB. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling. Molecular Cancer Research : McR. PMID 29133594 DOI: 10.1158/1541-7786.Mcr-17-0468 |
0.489 |
|
| 2017 |
Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher W. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase. Chemmedchem. PMID 29072804 DOI: 10.1002/Cmdc.201700663 |
0.41 |
|
| 2017 |
Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association. 6. PMID 29051215 DOI: 10.1161/Jaha.117.006635 |
0.482 |
|
| 2017 |
Jensen BC, Parry TL, Huang W, Beak JY, Ilaiwy A, Bain JR, Newgard CB, Muehlbauer MJ, Patterson C, Johnson GL, Willis MS. Effects of the Kinase Inhibitor Sorafenib on Heart, Muscle, Liver, and Plasma Metabolism In Vivo using Non-Targeted Metabolomics Analysis. British Journal of Pharmacology. PMID 28977680 DOI: 10.1111/Bph.14062 |
0.45 |
|
| 2017 |
Angus SP, Zawistowski JS, Johnson GL. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annual Review of Pharmacology and Toxicology. PMID 28934561 DOI: 10.1146/Annurev-Pharmtox-010617-052954 |
0.423 |
|
| 2017 |
Jensen BC, Parry TL, Huang W, Ilaiwy A, Bain JR, Muehlbauer MJ, O'Neal SK, Patterson C, Johnson GL, Willis MS. Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo. Metabolites. 7. PMID 28640223 DOI: 10.3390/Metabo7030031 |
0.322 |
|
| 2017 |
Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, ... Johnson GL, et al. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology. PMID 28486691 DOI: 10.1093/Neuonc/Nox052 |
0.413 |
|
| 2017 |
Cann ML, McDonald IM, East MP, Johnson GL, Graves LM. Measuring Kinase Activity - A Global Challenge. Journal of Cellular Biochemistry. PMID 28464261 DOI: 10.1002/Jcb.26103 |
0.484 |
|
| 2017 |
McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AE, ... ... Johnson GL, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology. PMID 28379424 DOI: 10.1093/Neuonc/Nox044 |
0.477 |
|
| 2017 |
Mobley RJ, Raghu D, Duke LD, Abell-Hart K, Zawistowski JS, Lutz K, Gomez SM, Roy S, Homayouni R, Johnson GL, Abell AN. MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. Cell Reports. 18: 2387-2400. PMID 28273454 DOI: 10.1016/J.Celrep.2017.02.030 |
0.39 |
|
| 2017 |
Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves L, Moorman NJ. Kinome Profiling Identifies Druggable Targets For Novel HCMV Antivirals. Molecular & Cellular Proteomics : McP. PMID 28237943 DOI: 10.1074/Mcp.M116.065375 |
0.434 |
|
| 2017 |
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, ... ... Johnson GL, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653 |
0.401 |
|
| 2017 |
Angus SP, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher KK, Forero A, Krop IE, Thompson AM, Murthy RK, He X, Perou CM, Earp S, Carey LA, ... Johnson GL, et al. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal of Clinical Oncology. 35: 1027-1027. DOI: 10.1200/Jco.2017.35.15_Suppl.1027 |
0.337 |
|
| 2017 |
Velarde SH, Usary J, Perou C, Johnson GL. Abstract A30: Kinome dynamics in triple negative breast cancer in response to chemotherapy Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A30 |
0.335 |
|
| 2017 |
Swearingen AEDV, Sambade MJ, Siegel MB, Sud S, Bevill SM, Golitz BT, Bash RE, Santos CM, Darr DB, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A03 |
0.388 |
|
| 2016 |
Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL, Kissil JL. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget. PMID 27363027 DOI: 10.18632/Oncotarget.10248 |
0.419 |
|
| 2016 |
Stuhlmiller TJ, Miller SM, Johnson GL. Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains. Molecular & Cellular Oncology. 3: e1052182. PMID 27308566 DOI: 10.1080/23723556.2015.1052182 |
0.416 |
|
| 2016 |
Miller SM, Goulet DR, Johnson GL. Targeting the breast cancer kinome. Journal of Cellular Physiology. PMID 27186656 DOI: 10.1002/Jcp.25427 |
0.416 |
|
| 2016 |
Bradford D, Whitcomb P, Dombi E, Chen AP, Baldwin A, Wolters P, Martin S, Glod J, Derdak J, Coyne GHO, Cowen EW, Holmblad M, Trepel J, Wood BJ, Paul SM, ... ... Johnson GL, et al. Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2596 |
0.304 |
|
| 2016 |
Stuhlmiller TJ, Miller SM, Zawistowski JS, Duncan JS, Angus SP, Granger DA, Reuther RA, Collins KAL, Shawn GM, Kuan P, Chen X, Sciaky N, Johnson GL. Abstract B25: BET bromodomain inhibition targets adaptive responses to lapatinib in HER2-positive breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B25 |
0.502 |
|
| 2016 |
Zawistowski JS, Miller SM, Goulet DR, Stuhlmiller TJ, Singh D, Sciaky N, Velarde SH, Angus SP, Johnson GL. Abstract B24: Triple-negative breast cancer adaptive response to MEK inhibition is regulated by the induction of super-enhancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B24 |
0.455 |
|
| 2016 |
Miller SM, Zawistowski JS, Stuhlmiller TJ, Sciaky N, Santos CM, Darr DB, Johnson GL. Abstract B21: Suppression of adaptive resistance mechanisms to trametinib by inhibition of BET bromodomains in TNBC Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B21 |
0.499 |
|
| 2016 |
Yesilkanal AE, Frankenberger C, Rabe DC, Johnson GL, Rosner MR. Abstract 1620: Elucidating metastatic signaling networks in TNBC by investigating RKIP-regulated kinome Cancer Research. 76: 1620-1620. DOI: 10.1158/1538-7445.Tummet15-B23 |
0.48 |
|
| 2016 |
Wang X, Erdmann-Gilmore P, Viner R, Meyer M, Stuhlmiller T, Davies S, Li S, Zhang Q, Mooradian A, Huang K, Bomgarden R, Ding L, Ellis M, Rogers J, Johnson G, et al. Abstract LB-267: The proteomic landscape of patient-derived breast cancer xenografts reveals tumor-specific differences in the breast tumor microenvironment Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-267 |
0.343 |
|
| 2016 |
Swearingen AEDV, Sambade MJ, Sud S, Golitz B, Johnson GL, Anders CK. Abstract 3867: Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models Cancer Research. 76: 3867-3867. DOI: 10.1158/1538-7445.Am2016-3867 |
0.359 |
|
| 2015 |
Ahmad S, Johnson GL, Scott JE. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochemical and Biophysical Research Communications. PMID 26056008 DOI: 10.1016/J.Bbrc.2015.06.029 |
0.431 |
|
| 2015 |
Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, ... ... Johnson GL, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/J.Celrep.2015.03.037 |
0.483 |
|
| 2015 |
Tignanelli CJ, Stratford J, Moffitt R, Reuther R, Johnson GL, Yeh JJ. Abstract B71: Multiplexed kinase inhibitor beads identify multiple pathways of resistance to PI3K inhibition facilitating the rational selection of novel combination therapies in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B71 |
0.44 |
|
| 2015 |
Yesilkanal AE, Frankenberger C, Rabe D, Johnson GL, Rosner MR. Abstract 3251: Regulation of TNBC kinome by the metastasis suppressor Raf kinase inhibitory protein (RKIP) Cancer Research. 75: 3251-3251. DOI: 10.1158/1538-7445.Am2015-3251 |
0.459 |
|
| 2015 |
Swearingen AEDV, Siegel MB, Sambade MJ, Sud S, Miller SM, Silva G, Bash RE, Santos CM, Darr DB, Golitz B, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models Cancer Research. 75: 2579-2579. DOI: 10.1158/1538-7445.Am2015-2579 |
0.376 |
|
| 2015 |
McNeill RS, Canoutas DA, Schmid RS, Bash RE, Constance BH, Azam SH, Reuther RA, Johnson GL, Miller CR. Atps-55Influence Of Mapk And Pi3K Pathway Mutations On Response To Targeted Inhibitors Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.55 |
0.404 |
|
| 2014 |
Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 86: 121-5. PMID 25257766 DOI: 10.1016/J.Lungcan.2014.09.005 |
0.346 |
|
| 2014 |
Zawistowski JS, Graves LM, Johnson GL. Assessing adaptation of the cancer kinome in response to targeted therapies. Biochemical Society Transactions. 42: 765-9. PMID 25109955 DOI: 10.1042/Bst20130274 |
0.497 |
|
| 2014 |
Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2516-22. PMID 24664307 DOI: 10.1158/1078-0432.Ccr-13-1081 |
0.503 |
|
| 2014 |
Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW. An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Molecular & Cellular Proteomics : McP. 13: 1184-97. PMID 24556848 DOI: 10.1074/Mcp.M113.037374 |
0.463 |
|
| 2014 |
Swearingen AEDV, Siegel MB, Bash R, Golitz B, Santos C, Darr D, Parker J, Johnson GL, Miller CR, Anders CK. Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-5449A |
0.321 |
|
| 2014 |
Angus SP, Stuhlmiller TJ, Reuther R, Pham TT, Granger DA, Darr DB, Jordan JL, Moschos SJ, Johnson GL, Sharpless NE. Abstract 4761: Defining the adaptive kinome response to BRAF and MEK inhibition in melanoma Cancer Research. 74: 4761-4761. DOI: 10.1158/1538-7445.Am2014-4761 |
0.475 |
|
| 2014 |
Liu J, Yang C, Simpson C, DeRyckere D, Deusen AV, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, et al. Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia Acs Medicinal Chemistry Letters. 5: 1173-1173. DOI: 10.1021/Ml500328M |
0.364 |
|
| 2013 |
Pham TT, Angus SP, Johnson GL. MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & Cancer. 4: 419-26. PMID 24386504 DOI: 10.1177/1947601913513950 |
0.511 |
|
| 2013 |
Wu C, Haynes EM, Asokan SB, Simon JM, Sharpless NE, Baldwin AS, Davis IJ, Johnson GL, Bear JE. Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. The Journal of Cell Biology. 203: 907-16. PMID 24344184 DOI: 10.1083/Jcb.201306032 |
0.366 |
|
| 2013 |
Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Johnson GL, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040 |
0.404 |
|
| 2013 |
Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, ... Johnson GL, et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. Plos One. 8: e66755. PMID 23826126 DOI: 10.1371/Journal.Pone.0066755 |
0.5 |
|
| 2013 |
Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/Mcb.01443-12 |
0.344 |
|
| 2013 |
Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Molecular and Cellular Biology. 33: 2260-74. PMID 23530058 DOI: 10.1128/Mcb.00269-13 |
0.328 |
|
| 2013 |
Dillon PJ, Gregory SM, Tamburro K, Sanders MK, Johnson GL, Raab-Traub N, Dittmer DP, Damania B. Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host & Microbe. 13: 204-14. PMID 23414760 DOI: 10.1016/J.Chom.2012.12.005 |
0.37 |
|
| 2013 |
Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. The Biochemical Journal. 450: 1-8. PMID 23343193 DOI: 10.1042/Bj20121456 |
0.446 |
|
| 2013 |
Ahmad S, Hughes MA, Johnson GL, Scott JE. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. Journal of Biomolecular Screening. 18: 388-99. PMID 23134735 DOI: 10.1177/1087057112466430 |
0.376 |
|
| 2013 |
Richardson BT, Dibble CF, Borikova AL, Johnson GL. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biological Chemistry. 394: 35-42. PMID 23096573 DOI: 10.1515/Hsz-2012-0243 |
0.384 |
|
| 2013 |
Johnson GL, Amos KD, Duncan JS, Whittle M, Zawistowki J, Goulet D, He X, Noe J, Perou CM, Earp S, Carey LA. Kinome reprogramming response to MEK inhibition: A window-of-opportunity trial in triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: 512-512. DOI: 10.1200/Jco.2013.31.15_Suppl.512 |
0.415 |
|
| 2013 |
Johnson G. Abstract SY10-02: Breast cancer subtypes have selective kinome reprogramming in response to kinase inhibitors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy10-02 |
0.389 |
|
| 2012 |
Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.Ccr-12-0563 |
0.404 |
|
| 2012 |
Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Acs Medicinal Chemistry Letters. 3: 129-134. PMID 22662287 DOI: 10.1021/Ml200239K |
0.446 |
|
| 2012 |
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Johnson GL, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053 |
0.466 |
|
| 2012 |
Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS, Graves LM, Gomez SM, Johnson GL. Defining the expressed breast cancer kinome. Cell Research. 22: 620-3. PMID 22310242 DOI: 10.1038/Cr.2012.25 |
0.428 |
|
| 2012 |
Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL. Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. Oncogene. 31: 3889-900. PMID 22139075 DOI: 10.1038/Onc.2011.544 |
0.462 |
|
| 2012 |
Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, ... ... Johnson GL, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607 |
0.361 |
|
| 2012 |
Whittle MC, Duncan JS, Graves LM, Johnson GL. Abstract B37: Monitoring kinome response to EGFR inhibition in triple negative breast cancer Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B37 |
0.416 |
|
| 2012 |
Duncan JS, Whittle MW, Graves LM, Johnson GL. Abstract B23: Reprogramming of the cancer kinome in response to targeted kinase inhibition Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B23 |
0.48 |
|
| 2011 |
Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 8: 525-37. PMID 21549327 DOI: 10.1016/J.Stem.2011.03.008 |
0.363 |
|
| 2011 |
Johnson GL. Defining MAPK interactomes. Acs Chemical Biology. 6: 18-20. PMID 21128644 DOI: 10.1021/Cb100384Z |
0.416 |
|
| 2011 |
Darzynkiewicz Z, Pozarowski P, Lee BW, Johnson GL. Fluorochrome-labeled inhibitors of caspases: convenient in vitro and in vivo markers of apoptotic cells for cytometric analysis. Methods in Molecular Biology (Clifton, N.J.). 682: 103-14. PMID 21057924 DOI: 10.1007/978-1-60327-409-8_9 |
0.314 |
|
| 2011 |
Christoph S, DeRyckere D, Sather S, Wang X, Kireev D, Janzen W, Liu J, Yang C, van Deusen A, Simpson C, Norris-Drouin J, Frye S, Earp HS, Johnson GL, Graham DK. UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL Blood. 118: 2589-2589. DOI: 10.1182/Blood.V118.21.2589.2589 |
0.44 |
|
| 2010 |
Nakamura K, Johnson GL. Activity assays for extracellular signal-regulated kinase 5. Methods in Molecular Biology (Clifton, N.J.). 661: 91-106. PMID 20811978 DOI: 10.1007/978-1-60761-795-2_5 |
0.547 |
|
| 2010 |
Konhilas JP, Boucek DM, Horn TR, Johnson GL, Leinwand LA. The role of MEKK1 in hypertrophic cardiomyopathy. International Heart Journal. 51: 277-84. PMID 20716846 DOI: 10.1536/Ihj.51.277 |
0.342 |
|
| 2010 |
Dibble CF, Horst JA, Malone MH, Park K, Temple B, Cheeseman H, Barbaro JR, Johnson GL, Bencharit S. Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. Plos One. 5: e11740. PMID 20668527 DOI: 10.1371/Journal.Pone.0011740 |
0.331 |
|
| 2010 |
Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. The Journal of Biological Chemistry. 285: 11760-4. PMID 20181950 DOI: 10.1074/Jbc.C109.097220 |
0.475 |
|
| 2010 |
Nakamura K, Kimple AJ, Siderovski DP, Johnson GL. PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. The Journal of Biological Chemistry. 285: 2077-89. PMID 19903815 DOI: 10.1074/Jbc.M109.065102 |
0.352 |
|
| 2009 |
Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G. Coordination of Rho GTPase activities during cell protrusion. Nature. 461: 99-103. PMID 19693013 DOI: 10.1038/Nature08242 |
0.416 |
|
| 2009 |
Johnson GL, Gomez SM. Sequence patches on MAPK surfaces define protein-protein interactions. Genome Biology. 10: 222. PMID 19519955 DOI: 10.1186/Gb-2009-10-6-222 |
0.381 |
|
| 2009 |
Frye SV, Johnson GL. Inhibitors paradoxically prime kinases. Nature Chemical Biology. 5: 448-9. PMID 19465930 DOI: 10.1038/Nchembio.F.11 |
0.462 |
|
| 2009 |
Crose LE, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. The Journal of Biological Chemistry. 284: 13301-5. PMID 19318350 DOI: 10.1074/Jbc.C900009200 |
0.337 |
|
| 2009 |
Abell AN, Granger DA, Johnson NL, Vincent-Jordan N, Dibble CF, Johnson GL. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Molecular and Cellular Biology. 29: 2748-61. PMID 19289495 DOI: 10.1128/Mcb.01391-08 |
0.517 |
|
| 2009 |
Xie L, Jing L, Yu Y, Nakamura K, Parker CE, Johnson GL, Chen X. In vivo profiling endogenous interactions with knock-out in mammalian cells. Analytical Chemistry. 81: 1411-7. PMID 19199569 DOI: 10.1021/Ac802161D |
0.374 |
|
| 2008 |
Wu Y, Johnson GL, Gomez SM. Data-driven modeling of cellular stimulation, signaling and output response in RAW 264.7 cells. Journal of Molecular Signaling. 3: 11. PMID 18498628 DOI: 10.1186/1750-2187-3-11 |
0.33 |
|
| 2008 |
Nakamura K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh LA, Johnson GL, Scott JE. Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization. Journal of Biomolecular Screening. 13: 396-405. PMID 18480472 DOI: 10.1177/1087057108318281 |
0.389 |
|
| 2008 |
Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 27: 4434-45. PMID 18372913 DOI: 10.1038/Onc.2008.84 |
0.356 |
|
| 2008 |
Mendoza H, Campbell DG, Burness K, Hastie J, Ronkina N, Shim JH, Arthur JS, Davis RJ, Gaestel M, Johnson GL, Ghosh S, Cohen P. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. The Biochemical Journal. 409: 711-22. PMID 18021073 DOI: 10.1042/Bj20071149 |
0.519 |
|
| 2008 |
Stalheim L, Johnson GL. MAPK kinase kinase regulation of SAPK/JNK pathways Topics in Current Genetics. 20: 1-15. DOI: 10.1007/4735_2007_0238 |
0.39 |
|
| 2007 |
Hilder TL, Malone MH, Bencharit S, Colicelli J, Haystead TA, Johnson GL, Wu CC. Proteomic identification of the cerebral cavernous malformation signaling complex. Journal of Proteome Research. 6: 4343-55. PMID 17900104 DOI: 10.1021/Pr0704276 |
0.37 |
|
| 2007 |
Hilder TL, Malone MH, Johnson GL. Hyperosmotic induction of mitogen-activated protein kinase scaffolding. Methods in Enzymology. 428: 297-312. PMID 17875425 DOI: 10.1016/S0076-6879(07)28017-6 |
0.509 |
|
| 2007 |
Winter-Vann AM, Johnson GL. Integrated activation of MAP3Ks balances cell fate in response to stress. Journal of Cellular Biochemistry. 102: 848-58. PMID 17786929 DOI: 10.1002/Jcb.21522 |
0.465 |
|
| 2007 |
Abell AN, Granger DA, Johnson GL. MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta. The Journal of Biological Chemistry. 282: 30476-84. PMID 17726008 DOI: 10.1074/Jbc.M705783200 |
0.512 |
|
| 2007 |
Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 26: 3159-71. PMID 17496913 DOI: 10.1038/Sj.Onc.1210409 |
0.562 |
|
| 2007 |
Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene. 26: 3097-9. PMID 17496908 DOI: 10.1038/Sj.Onc.1210395 |
0.303 |
|
| 2007 |
Nakamura K, Johnson GL. Noncanonical function of MEKK2 and MEK5 PB1 domains for coordinated extracellular signal-regulated kinase 5 and c-Jun N-terminal kinase signaling. Molecular and Cellular Biology. 27: 4566-77. PMID 17452462 DOI: 10.1128/Mcb.00125-07 |
0.424 |
|
| 2007 |
Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochimica Et Biophysica Acta. 1773: 1341-8. PMID 17306896 DOI: 10.1016/J.Bbamcr.2006.12.009 |
0.448 |
|
| 2007 |
Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z. MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Molecular and Cellular Biology. 27: 510-7. PMID 17101801 DOI: 10.1128/Mcb.01355-06 |
0.364 |
|
| 2007 |
Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26: 2791-8. PMID 17057734 DOI: 10.1038/Sj.Onc.1210072 |
0.338 |
|
| 2006 |
Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, ... Johnson GL, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene. 25: 6092-100. PMID 16652142 DOI: 10.1038/Sj.Onc.1209633 |
0.406 |
|
| 2006 |
Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene. 25: 4998-5010. PMID 16568086 DOI: 10.1038/Sj.Onc.1209507 |
0.378 |
|
| 2006 |
Nakamura K, Uhlik MT, Johnson NL, Hahn KM, Johnson GL. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Molecular and Cellular Biology. 26: 2065-79. PMID 16507987 DOI: 10.1128/Mcb.26.6.2065-2079.2006 |
0.46 |
|
| 2005 |
Lapadat R, Debiasi RL, Johnson GL, Tyler KL, Shah I. Genes Induced by Reovirus Infection Have a Distinct Modular Cis-Regulatory Architecture. Current Genomics. 6: 501-513. PMID 23335855 DOI: 10.2174/138920205775067675 |
0.316 |
|
| 2005 |
Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Molecular and Cellular Biology. 25: 8948-59. PMID 16199873 DOI: 10.1128/Mcb.25.20.8948-8959.2005 |
0.709 |
|
| 2005 |
Abell AN, Johnson GL. MEKK4 is an effector of the embryonic TRAF4 for JNK activation. The Journal of Biological Chemistry. 280: 35793-6. PMID 16157600 DOI: 10.1074/Jbc.C500260200 |
0.537 |
|
| 2005 |
Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Human Molecular Genetics. 14: 2521-31. PMID 16037064 DOI: 10.1093/Hmg/Ddi256 |
0.324 |
|
| 2005 |
Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Current Opinion in Chemical Biology. 9: 325-31. PMID 15939336 DOI: 10.1016/J.Cbpa.2005.04.004 |
0.539 |
|
| 2005 |
Li Y, Minamino T, Tsukamoto O, Yujiri T, Shintani Y, Okada K, Nagamachi Y, Fujita M, Hirata A, Sanada S, Asanuma H, Takashima S, Hori M, Johnson GL, Kitakaze M. Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model. Circulation. 111: 1672-8. PMID 15795331 DOI: 10.1161/01.Cir.0000160350.20810.0F |
0.344 |
|
| 2005 |
Huang X, Lee B, Johnson G, Naleway J, Guzikowski A, Dai W, Darzynkiewicz Z. Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis Cell Cycle. 4: 140-147. PMID 15611638 DOI: 10.4161/Cc.4.1.1322 |
0.312 |
|
| 2005 |
Uhlik MT, Temple B, Bencharit S, Kimple AJ, Siderovski DP, Johnson GL. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. Journal of Molecular Biology. 345: 1-20. PMID 15567406 DOI: 10.1016/J.Jmb.2004.10.038 |
0.313 |
|
| 2005 |
Cuevas BD, Uhlik MT, Garrington TP, Johnson GL. MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability. Oncogene. 24: 801-9. PMID 15558021 DOI: 10.1038/Sj.Onc.1208239 |
0.5 |
|
| 2004 |
Uhlik MT, Abell AN, Cuevas BD, Nakamura K, Johnson GL. Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 82: 658-63. PMID 15674433 DOI: 10.1139/O04-114 |
0.516 |
|
| 2004 |
Clarke P, Meintzer SM, Wang Y, Moffitt LA, Richardson-Burns SM, Johnson GL, Tyler KL. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. Journal of Virology. 78: 13132-8. PMID 15542665 DOI: 10.1128/Jvi.78.23.13132-13138.2004 |
0.436 |
|
| 2004 |
Anderson MS, Knall C, Thurman G, Mann D, Cusack N, Johnson GL, Ambruso DR. CP-64131, an aminobenzazepine with cytokine-like properties, stimulates human neutrophil functions through the p38-MAPK pathway. Journal of Leukocyte Biology. 76: 477-83. PMID 15155776 DOI: 10.1189/Jlb.0903422 |
0.47 |
|
| 2004 |
Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL, Garrington TP. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. Journal of Cellular Physiology. 199: 140-8. PMID 14978743 DOI: 10.1002/Jcp.10457 |
0.809 |
|
| 2004 |
Abell AN, DeCathelineau AM, Weed SA, Ambruso DR, Riches DW, Johnson GL. Rac2D57N, a dominant inhibitory Rac2 mutant that inhibits p38 kinase signaling and prevents surface ruffling in bone-marrow-derived macrophages. Journal of Cell Science. 117: 243-55. PMID 14676277 DOI: 10.1242/Jcs.00853 |
0.454 |
|
| 2004 |
Pozarowski P, Huang X, Halicka DH, Lee B, Johnson G, Darzynkiewicz Z. Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: a caution in data interpretation. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 55: 50-60. PMID 12938188 DOI: 10.1002/Cyto.A.10074 |
0.335 |
|
| 2003 |
Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, Horne EA, Dell'Acqua ML, Johnson GL. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nature Cell Biology. 5: 1104-10. PMID 14634666 DOI: 10.1038/Ncb1071 |
0.782 |
|
| 2003 |
Wei X, Sun W, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington T, Dakhama A, Lucas J, Johnson GL, Gelfand EW. MEF2C regulates c-Jun but not TNF-alpha gene expression in stimulated mast cells. European Journal of Immunology. 33: 2903-9. PMID 14515274 DOI: 10.1002/Eji.200324127 |
0.551 |
|
| 2003 |
Nakamura K, Johnson GL. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. The Journal of Biological Chemistry. 278: 36989-92. PMID 12912994 DOI: 10.1074/Jbc.C300313200 |
0.442 |
|
| 2003 |
DeBiasi RL, Clarke P, Meintzer S, Jotte R, Kleinschmidt-Demasters BK, Johnson GL, Tyler KL. Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis. Journal of Virology. 77: 8934-47. PMID 12885910 DOI: 10.1128/Jvi.77.16.8934-8947.2003 |
0.32 |
|
| 2003 |
Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson NL, Kesavan K, Ware M, Jones PL, Weed SA, DeBiasi RL, Oka Y, Tyler KL, Johnson GL. MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. The Embo Journal. 22: 3346-55. PMID 12839996 DOI: 10.1093/Emboj/Cdg322 |
0.81 |
|
| 2003 |
Sun W, Wei X, Kesavan K, Garrington TP, Fan R, Mei J, Anderson SM, Gelfand EW, Johnson GL. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Molecular and Cellular Biology. 23: 2298-308. PMID 12640115 DOI: 10.1128/Mcb.23.7.2298-2308.2003 |
0.573 |
|
| 2003 |
Witowsky J, Abell A, Johnson NL, Johnson GL, Cuevas BD. MEKK1 is required for inducible urokinase-type plasminogen activator expression. The Journal of Biological Chemistry. 278: 5941-6. PMID 12493778 DOI: 10.1074/Jbc.M212363200 |
0.815 |
|
| 2003 |
Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. The Journal of Biological Chemistry. 278: 1403-6. PMID 12456688 DOI: 10.1074/Jbc.C200616200 |
0.827 |
|
| 2002 |
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (New York, N.Y.). 298: 1911-2. PMID 12471242 DOI: 10.1126/Science.1072682 |
0.541 |
|
| 2002 |
Grabarek J, Du L, Johnson GL, Lee BW, Phelps DJ, Darzynkiewicz Z. Sequential activation of caspases and serine proteases (serpases) during apoptosis. Cell Cycle (Georgetown, Tex.). 1: 124-31. PMID 12429921 DOI: 10.4161/Cc.1.2.113 |
0.373 |
|
| 2002 |
Bild AH, Mendoza FJ, Gibson EM, Huang M, Villanueva J, Garrington TP, Jove R, Johnson GL, Gibson SB. MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage. Oncogene. 21: 6649-56. PMID 12242663 DOI: 10.1038/Sj.Onc.1205819 |
0.679 |
|
| 2002 |
Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nature Reviews. Molecular Cell Biology. 3: 663-72. PMID 12209126 DOI: 10.1038/Nrm906 |
0.521 |
|
| 2002 |
Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. The Journal of Clinical Investigation. 110: 271-9. PMID 12122119 DOI: 10.1172/Jci14938 |
0.375 |
|
| 2002 |
Darzynkiewicz Z, Bedner E, Smolewski P, Lee BW, Johnson GL. Detection of caspases activation in situ by fluorochrome-labeled inhibitors of caspases (FLICA). Methods in Molecular Biology (Clifton, N.J.). 203: 289-99. PMID 12073450 DOI: 10.1385/1-59259-179-5:289 |
0.32 |
|
| 2002 |
Kassenbrock CK, Hunter S, Garl P, Johnson GL, Anderson SM. Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. The Journal of Biological Chemistry. 277: 24967-75. PMID 11994282 DOI: 10.1074/Jbc.M201026200 |
0.532 |
|
| 2002 |
Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism Proceedings of the National Academy of Sciences of the United States of America. 99: 4608-4613. PMID 11930011 DOI: 10.1073/Pnas.072077299 |
0.389 |
|
| 2002 |
Smolewski P, Grabarek J, Lee BW, Johnson GL, Darzynkiewicz Z. Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-alpha or camptothecin assayed by the stathmo-apoptosis method. Cytometry. 47: 143-9. PMID 11891718 DOI: 10.1002/Cyto.10062 |
0.337 |
|
| 2002 |
Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, Schneider MD. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proceedings of the National Academy of Sciences of the United States of America. 99: 3866-71. PMID 11891332 DOI: 10.1073/Pnas.062453699 |
0.392 |
|
| 2002 |
Poggioli GJ, DeBiasi RL, Bickel R, Jotte R, Spalding A, Johnson GL, Tyler KL. Reovirus-induced alterations in gene expression related to cell cycle regulation. Journal of Virology. 76: 2585-94. PMID 11861824 DOI: 10.1128/Jvi.76.6.2585-2594.2002 |
0.701 |
|
| 2002 |
Johnson G. Scaffolding proteins - More than meets the eye Science. 295: 1249-1250. PMID 11847330 DOI: 10.1126/Science.1069828 |
0.42 |
|
| 2002 |
Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, Tyler KL, Johnson GL. TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene. 21: 260-71. PMID 11803469 DOI: 10.1038/Sj.Onc.1205048 |
0.702 |
|
| 2002 |
Schlesinger TK, Bonvin C, Jarpe MB, Fanger GR, Cardinaux JR, Johnson GL, Widmann C. Apoptosis stimulated by the 91-kDa caspase cleavage MEKK1 fragment requires translocation to soluble cellular compartments. The Journal of Biological Chemistry. 277: 10283-91. PMID 11782455 DOI: 10.1074/Jbc.M106885200 |
0.49 |
|
| 2002 |
Bonvin C, Guillon A, van Bemmelen MX, Gerwins P, Johnson GL, Widmann C. Role of the amino-terminal domains of MEKKs in the activation of NF kappa B and MAPK pathways and in the regulation of cell proliferation and apoptosis. Cellular Signalling. 14: 123-31. PMID 11781136 DOI: 10.1016/S0898-6568(01)00219-4 |
0.521 |
|
| 2002 |
Wei X, Wei R, Garrington T, Johnson GL, Gelfand EW. MEKK2-MEK5-BMK1/ERK5-MEF2C activation: A new pathway regulating c-jun gene expression in stimulated mast cells The Journal of Allergy and Clinical Immunology. 109. DOI: 10.1016/S0091-6749(02)82133-9 |
0.432 |
|
| 2001 |
Clarke P, Meintzer SM, Widmann C, Johnson GL, Tyler KL. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun Journal of Virology. 75: 11275-11283. PMID 11689607 DOI: 10.1128/Jvi.75.23.11275-11283.2001 |
0.496 |
|
| 2001 |
Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene. 20: 6910-9. PMID 11687970 DOI: 10.1038/Sj.Onc.1204842 |
0.654 |
|
| 2001 |
Amstad PA, Yu G, Johnson GL, Lee BW, Dhawan S, Phelps DJ. Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors. Biotechniques. 31: 608-616. PMID 11570504 DOI: 10.2144/01313Pf01 |
0.313 |
|
| 2001 |
Widmann C, Sather S, Oyer R, Johnson GL, Dreskin SC. In vitro activity of MEKK2 and MEKK3 in detergents is a function of a valine to serine difference in the catalytic domain Biochimica Et Biophysica Acta - Protein Structure and Molecular Enzymology. 1547: 167-173. PMID 11343802 DOI: 10.1016/S0167-4838(01)00183-2 |
0.5 |
|
| 2001 |
Chayama K, Papst PJ, Garrington TP, Pratt JC, Ishizuka T, Webb S, Ganiatsas S, Zon LI, Sun W, Johnson GL, Gelfand EW. Role of MEKK2-MEK5 in the regulation of TNF-alpha gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells. Proceedings of the National Academy of Sciences of the United States of America. 98: 4599-604. PMID 11274363 DOI: 10.1073/Pnas.081021898 |
0.55 |
|
| 2001 |
Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, Gelfand EW, Johnson GL. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. Journal of Biological Chemistry. 276: 5093-5100. PMID 11073940 DOI: 10.1074/Jbc.M003719200 |
0.552 |
|
| 2000 |
Avdi NJ, Nick JA, Whitlock BB, Billstrom MA, Henson PM, Johnson GL, Worthen GS. Tumor necrosis factor-alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils. Integrin involvement in a pathway leading from cytoplasmic tyrosine kinases apoptosis. The Journal of Biological Chemistry. 276: 2189-99. PMID 11053415 DOI: 10.1074/Jbc.M007527200 |
0.498 |
|
| 2000 |
Garrington TP, Ishizuka T, Papst PJ, Chayama K, Webb S, Yujiri T, Sun W, Sather S, Russell DM, Gibson SB, Keller G, Gelfand EW, Johnson GL. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. The Embo Journal. 19: 5387-95. PMID 11032806 DOI: 10.1093/Emboj/19.20.5387 |
0.495 |
|
| 2000 |
Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, Tyler KL. Reovirus-induced apoptosis is mediated by TRAIL Journal of Virology. 74: 8135-8139. PMID 10933724 DOI: 10.1128/Jvi.74.17.8135-8139.2000 |
0.341 |
|
| 2000 |
Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G, Kufe D. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Molecular and Cellular Biology. 20: 4979-89. PMID 10866655 DOI: 10.1128/Mcb.20.14.4979-4989.2000 |
0.477 |
|
| 2000 |
Yujiri T, Ware M, Widmann C, Oyer R, Russell D, Chan E, Zaitsu Y, Clarke P, Tyler K, Oka Y, Fanger GR, Henson P, Johnson GL. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation Proceedings of the National Academy of Sciences of the United States of America. 97: 7272-7277. PMID 10852963 DOI: 10.1073/Pnas.130176697 |
0.538 |
|
| 2000 |
Sakata N, Hamelmann E, Siadak AW, Terada N, Gerwins P, Aruffo A, Johnson GL, Gelfand EW. Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes. Cellular Immunology. 201: 109-123. PMID 10831320 DOI: 10.1006/Cimm.2000.1645 |
0.379 |
|
| 2000 |
Sun W, Vincent S, Settleman J, Johnson GL. MEK kinase 2 binds and activates protein kinase C-related kinase 2. Bifurcation of kinase regulatory pathways at the level of an MAPK kinase kinase. Journal of Biological Chemistry. 275: 24421-24428. PMID 10818102 DOI: 10.1074/Jbc.M003148200 |
0.515 |
|
| 2000 |
Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, Thurman G, Gonzalez-Aller C, Hiester A, DeBoer M, Harbeck RJ, Oyer R, Johnson GL, Roos D. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation Proceedings of the National Academy of Sciences of the United States of America. 97: 4654-4659. PMID 10758162 DOI: 10.1073/Pnas.080074897 |
0.308 |
|
| 2000 |
Sakata N, Kawasome H, Terada N, Johnson GL, Gelfand EW. CD40 and adenosine A2 receptor agonist-cyclic adenosine monophosphate rescue B-cell antigen receptor-induced apoptosis through independent pathways and converge to prevent caspase activation The Journal of Allergy and Clinical Immunology. 105: 522-531. PMID 10719303 DOI: 10.1067/Mai.2000.104251 |
0.383 |
|
| 2000 |
Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Molecular and Cellular Biology. 20: 205-12. PMID 10594023 DOI: 10.1128/Mcb.20.1.205-212.2000 |
0.716 |
|
| 1999 |
Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N. MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes Proceedings of the National Academy of Sciences of the United States of America. 96: 15127-15132. PMID 10611349 DOI: 10.1073/Pnas.96.26.15127 |
0.393 |
|
| 1999 |
Schlesinger TK, Demali KA, Johnson GL, Kazlauskas A. Platelet-derived growth factor-dependent association of the GTPase-activating protein of Ras and Src. The Biochemical Journal. 344: 519-26. PMID 10567236 DOI: 10.1042/Bj3440519 |
0.508 |
|
| 1999 |
Schaefer BC, Ware MF, Marrack P, Fanger GR, Kappler JW, Johnson GL, Monks CR. Live cell fluorescence imaging of T cell MEKK2: redistribution and activation in response to antigen stimulation of the T cell receptor. Immunity. 11: 411-21. PMID 10549623 DOI: 10.1016/S1074-7613(00)80116-8 |
0.395 |
|
| 1999 |
Sakata N, Kawasome H, Terada N, Gerwins P, Johnson GL, Gelfand EW. Differential activation and regulation of mitogen-activated protein kinases through the antigen receptor and CD40 in human B cells. European Journal of Immunology. 29: 2999-3008. PMID 10508274 DOI: 10.1002/(Sici)1521-4141(199909)29:09<2999::Aid-Immu2999>3.0.Co;2-L |
0.484 |
|
| 1999 |
Nick JA, Avdi NJ, Young SK, McDonald PP, Billstrom MA, Henson PM, Johnson GL, Worthen GS. An intracellular signaling pathway linking lipopolysaccharide stimulation to cellular responses of the human neutrophil: the p38 MAP kinase cascade and its functional significance. Chest. 116: 54S-55S. PMID 10424591 DOI: 10.1378/Chest.116.Suppl_1.54S |
0.417 |
|
| 1999 |
Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis REQUIREMENT FOR Akt ACTIVATION Journal of Biological Chemistry. 274: 17612-17618. PMID 10364198 DOI: 10.1074/Jbc.274.25.17612 |
0.496 |
|
| 1999 |
Yujiri T, Fanger GR, Garrington TP, Schlesinger TK, Gibson S, Johnson GL. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. Journal of Biological Chemistry. 274: 12605-12610. PMID 10212239 DOI: 10.1074/Jbc.274.18.12605 |
0.515 |
|
| 1999 |
Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways Current Opinion in Cell Biology. 11: 211-218. PMID 10209154 DOI: 10.1016/S0955-0674(99)80028-3 |
0.521 |
|
| 1999 |
Gibson S, Widmann C, Johnson GL. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. Journal of Biological Chemistry. 274: 10916-10922. PMID 10196170 DOI: 10.1074/Jbc.274.16.10916 |
0.48 |
|
| 1999 |
Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, Worthen GS. Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. The Journal of Clinical Investigation. 103: 851-8. PMID 10079106 DOI: 10.1172/Jci5257 |
0.457 |
|
| 1999 |
Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-Activated Protein Kinase: Conservation of a Three-Kinase Module From Yeast to Human Physical Review. 79: 143-180. PMID 9922370 DOI: 10.1152/Physrev.1999.79.1.143 |
0.481 |
|
| 1998 |
Knall C, Johnson GL. G-protein regulatory pathways: Rocketing into the twenty-first century. Journal of Cellular Biochemistry. 72: 137-146. PMID 29345839 DOI: 10.1002/(Sici)1097-4644(1998)72:30/31+<137::Aid-Jcb18>3.0.Co;2-L |
0.443 |
|
| 1998 |
Yujiri T, Sather S, Fanger GR, Johnson GL. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption Science. 282: 1911-1914. PMID 9836645 DOI: 10.1126/Science.282.5395.1911 |
0.554 |
|
| 1998 |
Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, Fanger GR, Gelfand EW, Johnson GL. Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death Oncogene. 17: 1475-1482. PMID 9779994 DOI: 10.1038/Sj.Onc.1202183 |
0.381 |
|
| 1998 |
McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, Johnson GL. Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF. Journal of Leukocyte Biology. 64: 537-45. PMID 9766635 DOI: 10.1002/Jlb.64.4.537 |
0.455 |
|
| 1998 |
Billstrom MA, Johnson GL, Avdi NJ, Worthen GS. Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection Journal of Virology. 72: 5535-5544. PMID 9621010 DOI: 10.1128/Jvi.72.7.5535-5544.1998 |
0.364 |
|
| 1998 |
Kawasome H, Papst P, Webb S, Keller GM, Johnson GL, Gelfand EW, Terada N. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity Proceedings of the National Academy of Sciences of the United States of America. 95: 5033-5038. PMID 9560223 DOI: 10.1073/Pnas.95.9.5033 |
0.423 |
|
| 1998 |
Widmann C, Gerwins P, Johnson NL, Jarpe MB, Johnson GL. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Molecular and Cellular Biology. 18: 2416-2429. PMID 9528810 DOI: 10.1128/Mcb.18.4.2416 |
0.519 |
|
| 1998 |
Widmann C, Gibson S, Johnson GL. Caspase-dependent Cleavage of Signaling Proteins during Apoptosis A TURN-OFF MECHANISM FOR ANTI-APOPTOTIC SIGNALS Journal of Biological Chemistry. 273: 7141-7147. PMID 9507028 DOI: 10.1074/Jbc.273.12.7141 |
0.532 |
|
| 1998 |
Fanger GR, Widmann C, Porter AC, Sather S, Johnson GL, Vaillancourt RR. 14-3-3 proteins interact with specific MEK kinases Journal of Biological Chemistry. 273: 3476-3483. PMID 9452471 DOI: 10.1074/Jbc.273.6.3476 |
0.455 |
|
| 1998 |
Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [d-Arg1,d-Phe5,d-Trp7,9,Leu11]Substance P Acts as a Biased Agonist toward Neuropeptide and Chemokine Receptors Journal of Biological Chemistry. 273: 3097-3104. PMID 9446627 DOI: 10.1074/Jbc.273.5.3097 |
0.342 |
|
| 1997 |
Widmann C, Johnson NL, Gardner AM, Smith RJ, Johnson GL. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene. 15: 2439-47. PMID 9395240 DOI: 10.1038/Sj.Onc.1201421 |
0.702 |
|
| 1997 |
Fanger GR, Johnson NL, Johnson GL. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 The Embo Journal. 16: 4961-4972. PMID 9305638 DOI: 10.1093/Emboj/16.16.4961 |
0.549 |
|
| 1997 |
Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell. 90: 315-23. PMID 9244305 DOI: 10.1016/S0092-8674(00)80339-6 |
0.465 |
|
| 1997 |
Ishizuka T, Terada N, Gerwins P, Hamelmann E, Oshiba A, Fanger GR, Johnson GL, Gelfand EW. Mast cell tumor necrosis factor alpha production is regulated by MEK kinases. Proceedings of the National Academy of Sciences of the United States of America. 94: 6358-63. PMID 9177222 DOI: 10.1073/Pnas.94.12.6358 |
0.52 |
|
| 1997 |
Knall C, Worthen GS, Johnson GL. Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases Proceedings of the National Academy of Sciences of the United States of America. 94: 3052-3057. PMID 9096344 DOI: 10.1073/Pnas.94.7.3052 |
0.542 |
|
| 1997 |
Gerwins P, Blank JL, Johnson GL. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. The Journal of Biological Chemistry. 272: 8288-95. PMID 9079650 DOI: 10.1074/Jbc.272.13.8288 |
0.539 |
|
| 1997 |
Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. The Journal of Clinical Investigation. 99: 975-86. PMID 9062356 DOI: 10.1172/Jci119263 |
0.521 |
|
| 1997 |
Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL. MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? Current Opinion in Genetics & Development. 7: 67-74. PMID 9024636 DOI: 10.1016/S0959-437X(97)80111-6 |
0.541 |
|
| 1997 |
Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin Potentiates Dexamethasone-Induced Apoptosis and Inhibits JNK Activity in Lymphoblastoid Cells Biochemical and Biophysical Research Communications. 230: 386-391. PMID 9016789 DOI: 10.1006/Bbrc.1996.5967 |
0.456 |
|
| 1997 |
Bunn P, Chan D, Johnson G, Heasley L, Stewart J, Gera L, Brenner D, Helfrich B. Anti-growth factor therapy for lung cancer Lung Cancer. 18: 10-11. DOI: 10.1016/S0169-5002(97)83860-3 |
0.531 |
|
| 1996 |
Avdi NJ, Winston BW, Russel M, Young SK, Johnson GL, Scott Worthent G. Activation of MEKK by formyl-methionyl-leucyl-phenylalanine in human neutrophils: Mapping pathways for mitogen-activated protein kinase activation Journal of Biological Chemistry. 271: 33598-33606. PMID 8969228 DOI: 10.1074/Jbc.271.52.33598 |
0.532 |
|
| 1996 |
Wang H, Johnson GL, Liu X, Malbon CC. Repression of Adipogenesis by Adenylyl Cyclase Stimulatory G-protein α Subunit Is Expressed within Region 146-220 Journal of Biological Chemistry. 271: 22022-22029. PMID 8703008 DOI: 10.1074/Jbc.271.36.22022 |
0.34 |
|
| 1996 |
Vaillancourt RR, Gardner AM, Kazlauskas A, Johnson GL. The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells. Oncogene. 13: 151-9. PMID 8700541 |
0.617 |
|
| 1996 |
Gardner AM, Johnson GL. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. The Journal of Biological Chemistry. 271: 14560-6. PMID 8662985 DOI: 10.1074/Jbc.271.24.14560 |
0.681 |
|
| 1996 |
Ishizuka T, Oshiba A, Sakata N, Terada N, Johnson GL, Gelfand EW. Aggregation of the FcϵRI on Mast Cells Stimulates c-Jun Amino-terminal Kinase Activity A RESPONSE INHIBITED BY WORTMANNIN Journal of Biological Chemistry. 271: 12762-12766. PMID 8662803 DOI: 10.1074/Jbc.271.22.12762 |
0.562 |
|
| 1996 |
Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. The Journal of Biological Chemistry. 271: 3229-37. PMID 8621725 DOI: 10.1074/Jbc.271.6.3229 |
0.718 |
|
| 1996 |
Blank JL, Gerwins P, Elliott EM, Sather S, Johnson GL. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3 regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase Journal of Biological Chemistry. 271: 5361-5368. PMID 8621389 DOI: 10.1074/Jbc.271.10.5361 |
0.536 |
|
| 1996 |
Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA, Johnson GL. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16. The Journal of Biological Chemistry. 271: 349-54. PMID 8550585 DOI: 10.1074/Jbc.271.1.349 |
0.689 |
|
| 1995 |
Qian NX, Russell M, Johnson GL. Acetylcholine muscarinic receptor regulation of the Ras/Raf/MAP kinase pathway. Life Sciences. 56: 945-9. PMID 10188797 DOI: 10.1016/0024-3205(95)00032-2 |
0.491 |
|
| 1995 |
Sakata N, Patel HR, Terada N, Aruffo A, Johnson GL, Gelfand EW. Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. Journal of Biological Chemistry. 270: 30823-30828. PMID 8530526 DOI: 10.1074/Jbc.270.51.30823 |
0.486 |
|
| 1995 |
Lange-Carter CA, Johnson GL. Assay of MEK kinases. Methods in Enzymology. 255: 290-301. PMID 8524113 DOI: 10.1016/S0076-6879(95)55032-1 |
0.456 |
|
| 1995 |
Winston BW, Lange-Carter CA, Gardner AM, Johnson GL, Riches DW. Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages. Proceedings of the National Academy of Sciences of the United States of America. 92: 1614-8. PMID 7878028 DOI: 10.1073/Pnas.92.5.1614 |
0.684 |
|
| 1995 |
Russell M, Lange-Carter CA, Johnson GL. Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) Journal of Biological Chemistry. 270: 11757-11760. PMID 7744823 DOI: 10.1074/Jbc.270.20.11757 |
0.488 |
|
| 1995 |
Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M. Identification of a dual specificity kinase that activates the jun kinases and p38-Mpk2 Science. 268: 286-290. PMID 7716521 DOI: 10.1126/Science.7716521 |
0.549 |
|
| 1995 |
Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocrine Reviews. 16: 259-70. PMID 7671848 DOI: 10.1210/Edrv-16-3-259 |
0.613 |
|
| 1995 |
Buhl AM, Osawa S, Johnson GL. Mitogen-activated Protein Kinase Activation Requires Two Signal Inputs from the Human Anaphylatoxin C5a Receptor Journal of Biological Chemistry. 270: 19828-19832. PMID 7649993 DOI: 10.1074/Jbc.270.34.19828 |
0.467 |
|
| 1995 |
Prasad MV, Dermott JM, Heasley LE, Johnson GL, Dhanasekaran N. Activation of Jun kinase/stress-activated protein kinase by GTPase-deficient mutants of G alpha 12 and G alpha 13. The Journal of Biological Chemistry. 270: 18655-9. PMID 7629196 DOI: 10.1074/Jbc.270.31.18655 |
0.628 |
|
| 1995 |
Mitchell FM, Russell M, Johnson GL. Differential calcium dependence in the activation of c-Jun kinase and mitogen-activated protein kinase by muscarinic acetylcholine receptors in rat 1a cells. The Biochemical Journal. 381-4. PMID 7625999 DOI: 10.1042/Bj3090381 |
0.453 |
|
| 1995 |
Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL. Gα12 and Gα13 Stimulate Rho-dependent Stress Fiber Formation and Focal Adhesion Assembly Journal of Biological Chemistry. 270: 24631-24634. PMID 7559569 DOI: 10.1074/Jbc.270.42.24631 |
0.326 |
|
| 1995 |
Vaillancourt RR, Heasley LE, Zamarripa J, Storey B, Valius M, Kazlauskas A, Johnson GL. Mitogen-activated protein kinase activation is insufficient for growth factor receptor-mediated PC12 cell differentiation. Molecular and Cellular Biology. 15: 3644-53. PMID 7540718 DOI: 10.1128/Mcb.15.7.3644 |
0.689 |
|
| 1995 |
Mitchell FM, Heasley LE, Qian NX, Zamarripa J, Johnson GL. Differential modulation of bombesin-stimulated phospholipase C beta and mitogen-activated protein kinase activity by [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P. The Journal of Biological Chemistry. 270: 8623-8. PMID 7536738 DOI: 10.1074/Jbc.270.15.8623 |
0.643 |
|
| 1995 |
Qian N, Mitchell FM, Johnson GL. Role of ras in muscarinic Ml and M2 acetylcholine receptor regulation of the mitogen-activated protein kinase stimulatory pathway Life Sciences. 56: 1030. DOI: 10.1016/0024-3205(95)93773-8 |
0.443 |
|
| 1994 |
Blumer KJ, Johnson GL, Lange-Carter CA. Mammalian mitogen-activated protein kinase kinase kinase (MEKK) can function in a yeast mitogen-activated protein kinase pathway downstream of protein kinase C. Proceedings of the National Academy of Sciences of the United States of America. 91: 4925-9. PMID 8197159 DOI: 10.1073/Pnas.91.11.4925 |
0.529 |
|
| 1994 |
Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. The Journal of Clinical Investigation. 93: 2134-40. PMID 8182145 DOI: 10.1172/Jci117209 |
0.655 |
|
| 1994 |
Lange-Carter CA, Pleiman C, Johnson GL. A Novel Upstream Activator in the Mitogen-Activated Protein Kinase Signal Transduction Pathway Recent Progress in Hormone Research. 49: 341-345. PMID 8146429 DOI: 10.1016/B978-0-12-571149-4.50022-2 |
0.537 |
|
| 1994 |
Russell M, Winitz S, Johnson GL. Acetylcholine muscarinic m1 receptor regulation of cyclic AMP synthesis controls growth factor stimulation of Raf activity. Molecular and Cellular Biology. 14: 2343-51. PMID 8139539 DOI: 10.1128/Mcb.14.4.2343 |
0.517 |
|
| 1994 |
Tordai A, Franklin RA, Patel H, Gardner AM, Johnson GL, Gelfand EW. Cross-linking of surface IgM stimulates the Ras/Raf-1/MEK/MAPK cascade in human B lymphocytes. The Journal of Biological Chemistry. 269: 7538-43. PMID 8125975 |
0.627 |
|
| 1994 |
Buhl AM, Avdi N, Worthen GS, Johnson GL. Mapping of the C5a receptor signal transduction network in human neutrophils Proceedings of the National Academy of Sciences of the United States of America. 91: 9190-9194. PMID 8090790 DOI: 10.1073/Pnas.91.19.9190 |
0.457 |
|
| 1994 |
Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends in Biochemical Sciences. 19: 236-40. PMID 8073500 DOI: 10.1016/0968-0004(94)90147-3 |
0.503 |
|
| 1994 |
Lange-Carter CA, Johnson GL. Ras-Dependent Growth Factor Regulation of MEK Kinase in PC12 Cells Science. 265: 1458-1461. PMID 8073291 DOI: 10.1126/Science.8073291 |
0.54 |
|
| 1994 |
Worthen GS, Avdi N, Buhl AM, Suzuki N, Johnson GL. FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase. Journal of Clinical Investigation. 94: 815-823. PMID 8040337 DOI: 10.1172/Jci117401 |
0.506 |
|
| 1994 |
Johnson GL, Vaillancourt RR. Sequential protein kinase reactions controlling cell growth and differentiation Current Opinion in Cell Biology. 6: 230-238. PMID 8024815 DOI: 10.1016/0955-0674(94)90141-4 |
0.518 |
|
| 1994 |
Gardner AM, Vaillancourt RR, Lange-Carter CA, Johnson GL. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Molecular Biology of the Cell. 5: 193-201. PMID 8019005 DOI: 10.1091/Mbc.5.2.193 |
0.682 |
|
| 1994 |
Johnson GL, Gardner AM, Lange-Carter C, Qian NX, Russell M, Winitz S. How does the G protein, Gi2, transduce mitogenic signals? Journal of Cellular Biochemistry. 54: 415-22. PMID 8014190 DOI: 10.1002/Jcb.240540408 |
0.694 |
|
| 1994 |
Minden A, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, Johnson GL, Karin M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK Science. 266: 1719-1723. PMID 7992057 DOI: 10.1126/Science.7992057 |
0.521 |
|
| 1994 |
Vaillancourt RR, Gardner AM, Johnson GL. B-Raf-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Molecular and Cellular Biology. 14: 6522-30. PMID 7935374 DOI: 10.1128/Mcb.14.10.6522 |
0.686 |
|
| 1994 |
Winitz S, Russell M, Johnson GL. Construction of mutant and chimeric G-protein alpha subunits. Methods in Enzymology. 237: 321-6. PMID 7935008 DOI: 10.1016/S0076-6879(94)37072-9 |
0.321 |
|
| 1994 |
Gardner AM, Lange-Carter CA, Vaillancourt RR, Johnson GL. Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Methods in Enzymology. 238: 258-70. PMID 7799792 DOI: 10.1016/0076-6879(94)38024-4 |
0.658 |
|
| 1993 |
Pleiman CM, Clark MR, Gauen LK, Winitz S, Coggeshall KM, Johnson GL, Shaw AS, Cambier JC. Mapping of sites on the Src family protein tyrosine kinases p55blk, p59fyn, and p56lyn which interact with the effector molecules phospholipase C-gamma 2, microtubule-associated protein kinase, GTPase-activating protein, and phosphatidylinositol 3-kinase. Molecular and Cellular Biology. 13: 5877-87. PMID 8395016 DOI: 10.1128/mcb.13.9.5877-5887.1993 |
0.507 |
|
| 1993 |
Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. The Journal of Biological Chemistry. 268: 17896-901. PMID 8394352 |
0.671 |
|
| 1993 |
Buhl AM, Eisfelder BJ, Worthen GS, Johnson GL, Russell M. Selective coupling of the human anaphylatoxin C5a receptor and α16 in human kidney 293 cells Febs Letters. 323: 132-134. PMID 8388335 DOI: 10.1016/0014-5793(93)81464-B |
0.307 |
|
| 1993 |
Wadzinski BE, Wheat WH, Jaspers S, Peruski LF, Lickteig RL, Johnson GL, Klemm DJ. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation Molecular and Cellular Biology. 13: 2822-2834. PMID 8386317 DOI: 10.1128/Mcb.13.5.2822 |
0.461 |
|
| 1993 |
Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science (New York, N.Y.). 260: 315-9. PMID 8385802 DOI: 10.1126/Science.8385802 |
0.689 |
|
| 1993 |
Qian NX, Winitz S, Johnson GL. Epitope-tagged Gq alpha subunits: expression of GTPase-deficient alpha subunits persistently stimulates phosphatidylinositol-specific phospholipase C but not mitogen-activated protein kinase activity regulated by the M1 muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America. 90: 4077-81. PMID 7683419 DOI: 10.1073/Pnas.90.9.4077 |
0.465 |
|
| 1993 |
Watkins DC, Johnson GL, Malbon CC. Regulation of the differentiation of teratocarcinoma cells into primitive endoderm by G alpha i2. Science (New York, N.Y.). 258: 1373-5. PMID 1455234 DOI: 10.1126/Science.1455234 |
0.359 |
|
| 1992 |
Gupta SK, Gallego C, Lowndes JM, Pleiman CM, Sable C, Eisfelder BJ, Johnson GL. Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Molecular and Cellular Biology. 12: 190-197. PMID 1729598 DOI: 10.1128/Mcb.12.1.190 |
0.345 |
|
| 1992 |
Johnson GL, Dhanasekaran N, Gupta SK, Lowndes JM, Vaillancourt RR, Ruoho AE. Genetic and structural analysis of G protein alpha subunit regulatory domains. Journal of Cellular Biochemistry. 47: 136-46. PMID 1661737 DOI: 10.1002/Jcb.240470207 |
0.358 |
|
| 1992 |
Gupta SK, Gallego C, Johnson GL. Mitogenic pathways regulated by G protein oncogenes. Molecular Biology of the Cell. 3: 123-128. PMID 1550954 DOI: 10.1091/Mbc.3.1.123 |
0.38 |
|
| 1992 |
Gallego C, Gupta SK, Winitz S, Eisfelder BJ, Johnson GL. Myristoylation of the G alpha i2 polypeptide, a G protein alpha subunit, is required for its signaling and transformation functions. Proceedings of the National Academy of Sciences of the United States of America. 89: 9695-9699. PMID 1409685 DOI: 10.1073/Pnas.89.20.9695 |
0.387 |
|
| 1992 |
Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL, Hoeffler JP. Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Molecular Endocrinology (Baltimore, Md.). 6: 2079-89. PMID 1337144 DOI: 10.1210/Mend.6.12.1337144 |
0.674 |
|
| 1992 |
Gallego C, Gupta SK, Heasley LE, Qian NX, Johnson GL. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proceedings of the National Academy of Sciences of the United States of America. 89: 7355-9. PMID 1323832 DOI: 10.1073/Pnas.89.16.7355 |
0.721 |
|
| 1992 |
Heasley LE, Johnson GL. The beta-PDGF receptor induces neuronal differentiation of PC12 cells. Molecular Biology of the Cell. 3: 545-53. PMID 1319243 DOI: 10.1091/Mbc.3.5.545 |
0.665 |
|
| 1991 |
Heasley LE, Benedict S, Gleavy J, Johnson GL. Requirement of the adenovirus E1A transformation domain 1 for inhibition of PC12 cell neuronal differentiation. Cell Regulation. 2: 479-89. PMID 1832020 DOI: 10.1091/Mbc.2.6.479 |
0.62 |
|
| 1991 |
Gupta SK, Dhanasekaran N, Heasley LE, Johnson GL. Activating mutations in the NH2- and COOH-terminal moieties of the Gs alpha subunit have dominant phenotypes and distinguishable kinetics of adenylyl cyclase stimulation. Journal of Cellular Biochemistry. 47: 359-68. PMID 1665495 DOI: 10.1002/Jcb.240470410 |
0.588 |
|
| 1990 |
Gupta SK, Diez E, Heasley LE, Osawa S, Johnson GL. A G protein mutant that inhibits thrombin and purinergic receptor activation of phospholipase A2. Science (New York, N.Y.). 249: 662-6. PMID 2166341 DOI: 10.1126/Science.2166341 |
0.592 |
|
| 1990 |
Weiss ER, Heller-Harrison RA, Diez E, Crasnier M, Malbon CC, Johnson GL. Rhodopsin expressed in Chinese hamster ovary cells regulates adenylyl cyclase activity. Journal of Molecular Endocrinology. 4: 71-9. PMID 2108693 DOI: 10.1677/Jme.0.0040071 |
0.424 |
|
| 1990 |
Osawa S, Heasley LE, Dhanasekaran N, Gupta SK, Woon CW, Berlot C, Johnson GL. Mutation of the Gs protein alpha subunit NH2 terminus relieves an attenuator function, resulting in constitutive adenylyl cyclase stimulation. Molecular and Cellular Biology. 10: 2931-40. PMID 1692962 DOI: 10.1128/Mcb.10.6.2931 |
0.587 |
|
| 1989 |
Johnson GL, Dhanasekaran N. The G-protein family and their interaction with receptors. Endocrine Reviews. 10: 317-31. PMID 2550214 DOI: 10.1210/Edrv-10-3-317 |
0.378 |
|
| 1989 |
Woon CW, Heasley L, Osawa S, Johnson GL. Mutation of glycine 49 to valine in the alpha subunit of GS results in the constitutive elevation of cyclic AMP synthesis. Biochemistry. 28: 4547-51. PMID 2548581 DOI: 10.1021/Bi00437A006 |
0.641 |
|
| 1988 |
Weiss ER, Kelleher DJ, Woon CW, Soparkar S, Osawa S, Heasley LE, Johnson GL. Receptor activation of G proteins. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 2: 2841-8. PMID 3139484 DOI: 10.1096/Fasebj.2.13.3139484 |
0.6 |
|
| 1987 |
Wolleben CD, McPherson RK, Rulfs J, Johnson GL, Miller TB. Phosphorylation of rat heart glycogen synthase: studies in cardiomyocytes and in vitro phosphorylations with cAMP-dependent kinase and protein phosphatase-1. Biochimica Et Biophysica Acta. 928: 98-106. PMID 3030451 DOI: 10.1016/0167-4889(87)90090-5 |
0.312 |
|
| 1980 |
Kaslow HR, Johnson GL, Brothers VM, Bourne HR. A regulatory component of adenylate cyclase from human erythrocyte membranes. The Journal of Biological Chemistry. 255: 3736-41. PMID 7364766 |
0.422 |
|
| 1980 |
Johnson GL, Kaslow HR, Farfel Z, Bourne HR. Genetic analysis of hormone-sensitive adenylate cyclase. Advances in Cyclic Nucleotide Research. 13: 1-37. PMID 6251703 |
0.409 |
|
| 1979 |
Kaslow HR, Farfel Z, Johnson GL, Bourne HR. Adenylate cyclase assembled in vitro: cholera toxin substrates determine different patterns of regulation by isoproterenol and guanosine 5'-triphosphate. Molecular Pharmacology. 15: 472-83. PMID 226858 |
0.47 |
|
| 1979 |
Johnson GL, Bourne HR, Gleason MK, Coffino P, Insel PA, Melmon KL. Isolation and characterization of S49 lymphoma cells deficient in beta-adrenergic receptors: relation of receptor number to activation of adenylate cyclase. Molecular Pharmacology. 15: 16-27. PMID 34089 |
0.476 |
|
| 1978 |
Johnson GL, Kaslow HR, Bourne HR. Reconstitution of cholera toxin-activated adenylate cyclase. Proceedings of the National Academy of Sciences of the United States of America. 75: 3113-7. PMID 277913 DOI: 10.1073/Pnas.75.7.3113 |
0.472 |
|
| 1978 |
Johnson GL, Kaslow HR, Bourne HR. Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase. The Journal of Biological Chemistry. 253: 7120-3. PMID 212417 |
0.512 |
|
| 1978 |
Naya-Vigne J, Johnson GL, Bourne HR, Coffino P. Complementation analysis of hormone-sensitive adenylate cyclase. Nature. 272: 720-2. PMID 205796 DOI: 10.1038/272720A0 |
0.489 |
|
| 1977 |
Johnson GL, Bourne HR. Influence of cholera toxin on the regulation of adenylate cyclase by GTP. Biochemical and Biophysical Research Communications. 78: 792-8. PMID 199187 DOI: 10.1016/0006-291X(77)90249-2 |
0.511 |
|
| 1975 |
Clark RB, Su YF, Ortmann R, Cubeddu L, Johnson GL, Perkins JP. Factors influencing the effect of hormones on the accumulation of cyclic AMP in cultured human astrocytoma cells. Metabolism: Clinical and Experimental. 24: 343-58. PMID 165356 DOI: 10.1016/0026-0495(75)90115-8 |
0.648 |
|
| Show low-probability matches. |
